IL123642A - Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration - Google Patents
Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regenerationInfo
- Publication number
- IL123642A IL123642A IL12364296A IL12364296A IL123642A IL 123642 A IL123642 A IL 123642A IL 12364296 A IL12364296 A IL 12364296A IL 12364296 A IL12364296 A IL 12364296A IL 123642 A IL123642 A IL 123642A
- Authority
- IL
- Israel
- Prior art keywords
- mononuclear phagocytes
- axonal regeneration
- pharmaceutical compositions
- mammal
- methods
- Prior art date
Links
- 210000002864 mononuclear phagocyte Anatomy 0.000 title abstract 4
- 230000003376 axonal effect Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 230000000735 allogeneic effect Effects 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000001616 monocyte Anatomy 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004207 dermis Anatomy 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52884595A | 1995-09-15 | 1995-09-15 | |
| US08/695,351 US5800812A (en) | 1995-09-15 | 1996-08-09 | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| PCT/US1996/014578 WO1997009885A1 (en) | 1995-09-15 | 1996-09-12 | Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL123642A0 IL123642A0 (en) | 1998-10-30 |
| IL123642A true IL123642A (en) | 2005-08-31 |
Family
ID=27062850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12364296A IL123642A (en) | 1995-09-15 | 1996-09-12 | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5800812A (de) |
| EP (1) | EP0952772B1 (de) |
| JP (1) | JP4100707B2 (de) |
| AT (1) | ATE290789T1 (de) |
| AU (1) | AU714205B2 (de) |
| CA (1) | CA2232262A1 (de) |
| DE (1) | DE69634499T2 (de) |
| DK (1) | DK0952772T3 (de) |
| ES (1) | ES2241002T3 (de) |
| IL (1) | IL123642A (de) |
| NZ (1) | NZ319365A (de) |
| PT (1) | PT952772E (de) |
| WO (1) | WO1997009885A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| US20010007657A1 (en) * | 1997-08-04 | 2001-07-12 | Reid James Steven | Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |
| US7795202B2 (en) * | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| CA2298506A1 (en) * | 1997-08-04 | 1999-02-11 | The Regents Of The University Of California | Methods for treating neurological deficits |
| JP2003532618A (ja) * | 1998-05-19 | 2003-11-05 | イエダ リサーチ アンド デベロプメント カンパニイ リミテッド | 細胞、神経系−特異的抗原およびそれらの用途 |
| US6541247B1 (en) | 1998-06-25 | 2003-04-01 | Neuronova Ab | Method of isolating ependymal neural stem cells |
| SE9802264D0 (sv) | 1998-06-25 | 1998-06-25 | Neuronova Ab | A method of isolating cells |
| IL125983A0 (en) * | 1998-08-30 | 1999-04-11 | Yeda Res & Dev | Pharmaceutical composition comprising factor xiiia |
| US20040120925A1 (en) * | 2001-03-12 | 2004-06-24 | Masahiro Toda | Remedies for nerve damages |
| KR101001119B1 (ko) * | 2001-11-21 | 2010-12-14 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 인간 단핵 식세포성 백혈구의 제조 방법 |
| JP2006503808A (ja) * | 2002-06-14 | 2006-02-02 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護及び神経再生用の抗原提示細胞 |
| US20090010873A1 (en) * | 2004-11-29 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis |
| RU2535966C2 (ru) * | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Клеточная терапия ишемической ткани |
| PT2790712T (pt) | 2011-12-14 | 2016-12-02 | Yeda Res & Dev | Subpopulação de monócitos humanos para o tratamento de lesões do sistema nervoso central |
| EP2999479B1 (de) | 2013-05-22 | 2021-01-06 | Yeda Research and Development Co., Ltd. | Subpopulation menschlicher monozyten zur behandlung von augenerkrankungen und -leiden |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157024A (en) * | 1977-10-16 | 1992-10-20 | Strategic Medical Research Corporation | Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals |
| IL71440A0 (en) * | 1984-04-04 | 1984-07-31 | Univ Ramot | Composition for nerve regeneration |
| US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| IL97365A0 (en) * | 1991-02-27 | 1992-05-25 | Yeda Res & Dev | Pharmaceutical compositions comprising a lymphokine |
| IL91459A0 (en) * | 1989-08-28 | 1990-04-29 | Yeda Res & Dev | Oligodendrocyte inhibitory factor |
-
1996
- 1996-08-09 US US08/695,351 patent/US5800812A/en not_active Expired - Lifetime
- 1996-09-12 DE DE69634499T patent/DE69634499T2/de not_active Expired - Lifetime
- 1996-09-12 JP JP51207797A patent/JP4100707B2/ja not_active Expired - Fee Related
- 1996-09-12 NZ NZ319365A patent/NZ319365A/xx not_active IP Right Cessation
- 1996-09-12 ES ES96932991T patent/ES2241002T3/es not_active Expired - Lifetime
- 1996-09-12 AU AU71572/96A patent/AU714205B2/en not_active Ceased
- 1996-09-12 AT AT96932991T patent/ATE290789T1/de not_active IP Right Cessation
- 1996-09-12 PT PT96932991T patent/PT952772E/pt unknown
- 1996-09-12 WO PCT/US1996/014578 patent/WO1997009885A1/en active IP Right Grant
- 1996-09-12 EP EP96932991A patent/EP0952772B1/de not_active Expired - Lifetime
- 1996-09-12 DK DK96932991T patent/DK0952772T3/da active
- 1996-09-12 CA CA002232262A patent/CA2232262A1/en not_active Abandoned
- 1996-09-12 IL IL12364296A patent/IL123642A/xx not_active IP Right Cessation
-
1997
- 1997-03-14 US US08/818,818 patent/US6117424A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11513370A (ja) | 1999-11-16 |
| AU7157296A (en) | 1997-04-01 |
| IL123642A0 (en) | 1998-10-30 |
| EP0952772A1 (de) | 1999-11-03 |
| NZ319365A (en) | 1999-08-30 |
| ATE290789T1 (de) | 2005-04-15 |
| EP0952772A4 (de) | 2002-01-02 |
| DK0952772T3 (da) | 2005-07-18 |
| DE69634499D1 (de) | 2005-04-21 |
| CA2232262A1 (en) | 1997-03-20 |
| PT952772E (pt) | 2005-07-29 |
| AU714205B2 (en) | 1999-12-23 |
| JP4100707B2 (ja) | 2008-06-11 |
| WO1997009885A1 (en) | 1997-03-20 |
| DE69634499T2 (de) | 2006-01-05 |
| EP0952772B1 (de) | 2005-03-16 |
| US5800812A (en) | 1998-09-01 |
| US6117424A (en) | 2000-09-12 |
| ES2241002T3 (es) | 2005-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
| ES2163034T3 (es) | Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. | |
| WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
| HUS1400034I1 (hu) | Dialkil-fumarátok alkalmazása autoimmun betegségek kezelésére szolgáló gyógyászati készítmények elõállítására | |
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| AR003989A1 (es) | Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica. | |
| PT1137436E (pt) | Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 | |
| HK1097449A1 (en) | Methods for in vivo delivery of biologics and compositions useful therefor | |
| MY122383A (en) | Cyclic boroproline compounds | |
| WO1996025947A3 (en) | Induction of e-selectin for targetting therapeutic agents | |
| DE69333775D1 (de) | Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten | |
| WO1998020932A3 (en) | Conditioning for allogeneic stem cell transplantation | |
| IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
| NZ505834A (en) | Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use | |
| CA2194485A1 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
| HU9601684D0 (en) | Deuterised active agents in transdermal application | |
| MXPA02011592A (es) | Composiciones de celulas dendriticas circulantes, humanas y metodos. | |
| EP1100515A4 (de) | Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten | |
| Mielcarek et al. | Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model | |
| ATE263833T1 (de) | Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen | |
| EP1152767B1 (de) | Verfahren zur herstellung antitumoraler th1-zellen | |
| FI941451A0 (fi) | Entsymaattisesti valmistettu dimeerinen IL-2 ja sen valmistuksessa käytettävä, hermoista johdettu transglutaminaasi | |
| UA32157A (uk) | Спосіб лікування діабетичної ретинопатії | |
| IT1274592B (it) | Composizione farmaceutica per la terapia tumorale contenente xenoantigeni | |
| AR027614A2 (es) | Compuesto de purina l-nucleosido, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |